Protocol Ledger

NCT04447118 · Phase III · COMPLETED

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Interventional Phase III clinical trial protocol NCT04447118 sponsored by Jiangsu HengRui Medicine Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-11 Enrollment: 151 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04447118
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)151 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04447118
Protocol FieldVerified Registry Value
NCT IdentifierNCT04447118
Consolidated Lead SponsorJiangsu HengRui Medicine Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment151 participants (ACTUAL)
Registered Start Date2020-09-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI